XML 37 R23.htm IDEA: XBRL DOCUMENT
v3.25.1

Equity Compensation Plan | 12 Months Ended
--- | ---
Dec. 31, 2024
Share-based Payment Arrangement [Abstract] |
Equity Compensation Plan | 12. Equity Compensation Plan In 2024 the Company’s shareholders and board of directors adopted an Equity Compensation Plan (“the Plan”), which replaced the Company’s previous equity compensation plan which was adopted in 2015 and expired in 2024 (the “2015 Plan”), under which the Company’s employees, directors or other persons or entities providing significant services to the Company or its subsidiaries are eligible to receive stock-based awards including restricted stock, restricted stock units, unrestricted stock, bonus stock, performance stock, stock appreciation rights and options to purchase common stock. The Plan is administered by the Compensation Committee of the Company’s board of directors and the aggregate number of shares of common stock reserved under this plan cannot exceed 10% of the number of shares of Company’s common stock issued and outstanding at the time any award is granted. The Company’s Board of Directors may terminate the Plan at any time. As of December 31, 2024, total of 2,699,612 restricted shares and options to purchase 922,000 common shares had been granted under the 2015 Plan and a total of 300,000 restricted shares and options to purchase 100,000 common shares have been granted under the Plan. Restricted shares On February 21, 2023, the Company granted 284,000 of non-vested restricted shares under the 2015 Plan to the Company’s CEO, non-executive members of Board of Directors of the Company and employees of the Manager. The fair value of each share granted was $2.85 which is equal to the market value of the Company’s common stock on that day. 50% of these shares vested on February 21, 2024 and the remaining 50% vest on February 21, 2025. On May 24, 2023, the Company granted 449,000 of non-vested restricted shares under the 2015 Plan to the Company’s CEO. The fair value of each share granted was $3.11 which is equal to the market value of the Company’s common stock on that day. These shares vested on November 24, 2023. On December 8, 2023, the Company granted 833,000 of non-vested restricted shares under the 2015 Plan to the Company’s CEO, non-executive members of Board of Directors of the Company and employees of the Manager. The fair value of each share granted was $6.43 which is equal to the market value of the Company’s common stock on that day. 50% of these shares vest on December 8, 2024 and the remaining 50% vest on December 8, 2025. On April 23, 2024, the Company granted 525,247 of non-vested restricted shares under the 2015 Plan to the Company’s CEO, non-executive members of Board of Directors of the Company and employees of the Manager. The fair value of each share granted was $6.01 which is equal to the market value of the Company’s common stock on that day. 50% of these shares vest on April 23, 2025 and the remaining 50% vest on April 23, 2026. On September 16, 2024, the Company granted 300,000 of non-vested restricted shares under the Plan to the Company’s CEO. The fair value of each share granted was $6.89 which is equal to the market value of the Company’s common stock on that day. 50% of these shares vest on September 16, 2025 and the remaining 50% vest on September 16, 2026. All unvested restricted shares are conditional upon the option holder’s continued service as an employee of the Company, or as a director until the applicable vesting date. Until the forfeiture of any restricted shares, the grantee has the right to vote such restricted shares, to receive and retain all regular cash dividends paid on such restricted shares and to exercise all other rights provided that the Company will retain custody of all distributions other than regular cash dividends made or declared with respect to the restricted shares. The Company pays dividends on all restricted shares regardless of whether they have vested and there is no obligation of the employee to return the dividend when employment ceases. The Company did not pay any dividends in the years ended December 31, 2022, 2023 and 2024. The stock based compensation expense for the vested and non-vested shares for the years ended December 31, 2022, 2023 and 2024 amounted to $462,508, $2,272,057 and $6,195,757, respectively, and is included in the consolidated statements of income under the caption “General and administrative expenses”. A summary of the status of the Company’s non-vested restricted shares as of December 31, 2022, 2023 and 2024, is presented below:
|  | Number of restricted shares |  |  | Weighted average grant date fair value per non- vested share |
Non-vested, January 1, 2022 |  |  | 343,744 |  |  |  | 2.99 |
Vested |  |  | (171,872 | ) |  |  | 2.99 |
Non-vested, December 31, 2022 |  |  | 171,872 |  |  |  | 2.99 |
Granted |  |  | 1,566,000 |  |  |  | 4.83 |
Vested |  |  | (620,872 | ) |  |  | 5.80 |
Non-vested, December 31, 2023 |  |  | 1,117,000 |  |  |  | 5.52 |
Granted |  |  | 825,247 |  |  |  | 6.33 |
Vested |  |  | (558,500 | ) |  |  | 5.52 |
Non-vested, December 31, 2024 |  |  | 1,383,747 |  |  |  | 4.51 |
The total fair value of shares vested during the years ended December 31, 2022, 2023 and 2024 was $465,773, $3,599,860 and $3,069,490, respectively, based on the closing share price at each vesting date. The remaining unrecognized compensation cost relating to the shares granted amounting to $4,420,683 as of December 31, 2024, is expected to be recognized over the remaining period of 1.7 years, according to the contractual terms of those non-vested share awards. Options to purchase common shares On February 21, 2023, the Company granted options to acquire up to 250,000 shares of common stock at an exercise price of $2.85 per share under the 2015 Plan to the Company’s CEO. 50% of these options vested on February 21, 2024 and the remaining 50% vest on February 21, 2025. These options expire on February 21, 2033. The fair value of each option granted was $1.47. The fair value of each option granted was estimated on the date of the grant using the Black-Scholes option pricing model. The following weighted-average assumptions were used in computing the fair value of the options granted: expected volatility of 50.20%; expected term of 5.75 years; risk-free interest rate of 4.06%. The expected term of the options granted was estimated to be the average of the vesting and the contractual term. The expected volatility was generally based on historical volatility as calculated using historical data during approximately 6 years prior to the grant date. 125,000 of these options were exercised on February 28, 2024 and 125,000 common shares were acquired for a total consideration of $356,250. On December 8, 2023, the Company granted options to acquire up to 299,000 shares of common stock at an exercise price of $6.43 per share under the 2015 Plan to the Company’s CEO and non-executive members of Board of Directors of the Company. 50% of these options vest on December 8, 2024 and the remaining 50% vest on December 8, 2025. These options expire on December 8, 2033. The fair value of each option granted was $3.39. The fair value of each option granted was estimated on the date of the grant using the Black-Scholes option pricing model. The following weighted-average assumptions were used in computing the fair value of the options granted: expected volatility of 51.44%; expected term of 5.75 years; risk-free interest rate of 4.17%. The expected term of the options granted was estimated to be the average of the vesting and the contractual term. The expected volatility was generally based on historical volatility as calculated using historical data during approximately 6 years prior to the grant date. On April 23, 2024, the Company granted options to acquire up to 123,000 shares of common stock at an exercise price of $6.01 per share under the 2015 Plan to the Company’s CEO, non-executive members of Board of Directors of the Company and employee of the Manager. 50% of these options vest on April 23, 2025 and the remaining 50% vest on April 23, 2026. These options expire on April 23, 2034. The fair value of each option granted was $3.22. The fair value of each option granted was estimated on the date of the grant using the Black-Scholes option pricing model. The following weighted-average assumptions were used in computing the fair value of the options granted: expected volatility of 52.11%; expected term of 5.75 years; risk-free interest rate of 4.53%. The expected term of the options granted was estimated to be the average of the vesting and the contractual term. The expected volatility was generally based on historical volatility as calculated using historical data during approximately 6 years prior to the grant date. On September 16, 2024, the Company granted options to acquire up to 100,000 shares of common stock at an exercise price of $6.89 per share under the Plan to the Company’s CEO. 50% of these options vest on September 16, 2025 and the remaining 50% vest on September 16, 2026. These options expire on September 16, 2034. The fair value of each option granted was $3.62. The fair value of each option granted was estimated on the date of the grant using the Black-Scholes option pricing model. The following weighted-average assumptions were used in computing the fair value of the options granted: expected volatility of 53.02%; expected term of 5.75 years; risk-free interest rate of 3.39%. The expected term of the options granted was estimated to be the average of the vesting and the contractual term. The expected volatility was generally based on historical volatility as calculated using historical data during approximately 6 years prior to the grant date. A summary of the Company’s non-vested stock option activity and related information for the years ended December 31, 2022, 2023 and 2024, is as follows:
|  | Option shares # |  |  | Weighted-Average Exercise Price $ |
Outstanding – January 31, 2022 |  |  | 250,000 |  |  |  | 2.99 |
Exercisable – January 31, 2022 |  |  | — |  |  |  | — |
Granted |  |  | — |  |  |  | — |
Outstanding – December 31, 2022 |  |  | 250,000 |  |  |  | 2.99 |
Exercisable – December 31, 2022 |  |  | 125,000 |  |  |  | 2.99 |
Unvested-December 31, 2022 |  |  | 125,000 |  |  |  | 2.99 |
Granted |  |  | 250,000 |  |  |  | 2.85 |
Granted |  |  | 299,000 |  |  |  | 6.43 |
Exercised |  |  | (250,000 | ) |  |  | 2.99 |
Outstanding – December 31, 2023 |  |  | 549,000 |  |  |  | 4.80 |
Exercisable – December 31, 2023 |  |  | — |  |  |  | — |
Unvested – December 31, 2023 |  |  | 549,000 |  |  |  | 4.80 |
Granted |  |  | 123,000 |  |  |  | 6.01 |
Granted |  |  | 100,000 |  |  |  | 6.89 |
Exercised |  |  | (125,000 | ) |  |  | 2.85 |
Outstanding – December 31, 2024 |  |  | 647,000 |  |  |  | 5.73 |
Exercisable – December 31, 2024 |  |  | 149,500 |  |  |  | 6.43 |
Unvested – December 31, 2024 |  |  | 497,500 |  |  |  | 5.52 |
125,000 options vested during the year ended December 31, 2022, 125,000 options vested and 250,000 options exercised during the year ended December 31, 2023 and 274,500 options vested of which 125,000 options were exercised during the year ended December 31, 2024. The remaining unrecognized compensation cost relating to the options granted amounting to $724,878 as of December 31, 2024, is expected to be recognized over the remaining period of 1.7 years, according to the contractual terms of those non-vested options. The stock based compensation expense for the vested and non-vested options for the years ended December 31, 2022, 2023 and 2024 amounted to $148,280, $317,349 and $1,131,051, respectively, and is included in the consolidated statements of income under the caption “General and administrative expenses”. As at December 31, 2024, the weighted average intrinsic value of outstanding stock options was $0.46 per option.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration